Alnylam Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | ALNY

Alnylam Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-7.092B, a 1.04% increase year-over-year.

  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $-7.01B, a 6.7% increase from 2022.
  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $-6.569B, a 20.8% increase from 2021.
  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $-5.438B, a 18.6% increase from 2020.

Alnylam Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | ALNY

  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $-7.01B, a 6.7% increase from 2022.
  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $-6.569B, a 20.8% increase from 2021.
  • Alnylam Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $-5.438B, a 18.6% increase from 2020.